Mastery EAQ Ch. 34

A  Strong contractions

B  Softened cervix

C  Midline fundus

D  Decreased pain

A  Pulmonary embolism

B  Renal failure

C  Ovarian failure

D  Abnormal vaginal bleeding

A  Blurred vision, Bradycardia, Increased diuresis

B  Anxiety, Dizziness, Blurred vision

C  Hirsutism, Dizziness,, Increased diuresis

D  Hirsutism, Bradycardia, Increased diuresis

A  For at least 1 month after starting the antibiotic

B  Until three throat cultures have been negative for the pathogen

C  During the entire period the patient is taking the antibiotic

D  For at least 6 weeks, starting at the end of the antibiotic regimen

A  Methylergonovine

B  Megestrol

C  Alendronate

D  Estradiol

A  Protamine sulfate

B  Calcium gluconate

C  Epinephrine

D  Atropine

A  Obtain a prescription for indomethacin.

B  Obtain a prescription for terbutaline.

C  Request a prescription to give calcium gluconate.

D  Decrease the drug dose immediately.

A  Immediately discontinue intravenous (IV) fluids.

B  Instruct the patient to bear down and push.

C  Place the patient on her left side.

D  Administer phentolamine mesylate.

A  Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

B  Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.

C  Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

D  Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.

A  Uterine atony

B  Pelvic inflammatory disease

C  Hypertension

D  Nausea and vomiting

A  Blood pressure

B  Uterine contractions

C  Blood glucose

D  Temperature

A  Vaginal bleeding at 38 weeks’ gestation

B  Absence of cervical ripening at 42 weeks’ gestation

C  Radiographic confirmation of cephalopelvic disproportion

D  Ineffective contractions in a full-term pregnancy

A  Low fluid intake

B  Cigarette use

C  Use of herbal supplements

D  Current tricyclic antidepressant use

A  Fetal movement, Uterine hyperactivity, Complete blood cell count

B  Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse

C  The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity

D  Uterine hyperactivity, Fetal heart rate, Complete blood cell count

A  Tamoxifen

B  Denosumab

C  Ibandronate

D  Calcitonin

A  Ask the patient to include soy in her diet.

B  Persuade the patient to start the therapy.

C  Advise the patient to engage in quiet activities.

D  Inform the patient about the benefits and risks of the therapy.

A  “The treatment should be started as soon as possible.”

B  “The therapy may cause thromboembolic events.”

C  “You may need to stop smoking during the therapy.”

D  “The treatment is likely to cause endometrial cancer.”

A  Terbutaline

B  Bed rest and hydration

C  Magnesium sulfate

D  Ritodrine

A  Antibiotic therapy

B  Anticonvulsant therapy

C  Hypertension

D  Diabetes

A  Norethindrone and ethinyl estradiol

B  Cervical cap with spermicidal jelly

C  Male condom with spermicidal jelly

D  Medroxyprogesterone

A  Allergy to salmon

B  Joint pain

C  Breast cancer

D  Current smoker

A  “Obtain a prescription for increasing the bisphosphonate dose.”

B  “Space the medications 1 to 2 hours apart.”

C  “Replace the bisphosphonate with calcitonin.”

D  “Discontinue the calcium supplement.”

A  “Perform weight-bearing exercise.”

B  “Report missed menstrual periods.”

C  “Have tests for serum cholesterol.”

D  “Have a yearly mammogram.”

A  “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”

B  “Estrogen levels inhibit the release of follicle-stimulating hormone.”

C  “High progesterone levels inhibit the release of luteinizing hormone.”

D  “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”

A  “I no longer experience hot flashes.”

B  “I have seen a great improvement in my sexual desire.”

C  “I have not experienced any uterine bleeding.”

D  “I am no longer experiencing painful intercourse.”

A  Metformin

B  Amoxicillin

C  Levothyroxine

D  Ferritin

A  Stimulates estrogen receptors on the bone to increase bone density

B  Contains estrogen, which stimulates bone reabsorption

C  Promotes bone absorption of calcium

D  Inhibits osteoclast-mediated bone reabsorption

A  Levothyroxine, Multivitamin

B  Atenolol, Levothyroxine

C  Multivitamin, Atenolol

D  Warfarin, Cholestyramine

A  “I will take the medication on an empty stomach and not lie down for 30 minutes.”

B  “This medication will help relieve the bone pain I have from my osteoporosis.”

C  “I need to take this medication with food to prevent damage to my esophagus.”

D  “I need to decrease my intake of dairy products to prevent hypercalcemia.”

A  Vertigo, Joint pain, Chest pain

B  Chest pain, Hot flashes, Loss of appetite

C  Hot flashes, Loss of appetite, Joint pain

D  Hot flashes, Vertigo, Loss of appetite

A  To induce cervical ripening

B  To treat gestational hypertension

C  To terminate pregnancy

D  To treat pelvic inflammatory disease

A  Consumption of saturated fats

B  Sedentary lifestyle

C  Increased body mass index (BMI)

D  Smoking heavily every day

A  Monotherapy with a progestin increases breast cancer risk.

B  Estrogen monotherapy increases the risk of breast cancer.

C  Estradiol with progestin increases the risk of endometrial cancer.

D  Unopposed estrogen increases the risk of endometrial cancer.

A  Terbutaline

B  Oxytocin

C  Prostaglandin E

D  Clomiphene

A  Medroxyprogesterone

B  Megestrol

C  Estropipate

D  Estrone

A  Brown discoloration of face

B  Yellow undertone to the skin

C  Hot flashes

D  Loss of hair

A  Suggest the patient take aluminum hydroxide with the medication.

B  Assess pulse oximetry continuously.

C  Monitor the patient’s blood pressure frequently.

D  Administer acetaminophen as needed.

A  Oxytocin

B  Clomiphene

C  Indomethacin

D  Dinoprostone

A  Progesterone

B  Ethinyl estradiol

C  Choriogonadotropin alfa

D  Clomiphene

A  Dysmenorrhea

B  Weight loss

C  Uterine bleeding

D  Deep vein thrombosis

A  “Endometrial cancer risk can be reduced by adding progestin.”

B  “The progestin in the regimen will help prevent breast cancer.”

C  “Vaginal cancer is prevented by adding progestin to the regimen.”

D  “The progestin in the regimen will help prevent ovarian cancer.”

A  Inhibition of the release of gonadotropins

B  Elevated progesterone levels inhibiting the release of the luteinizing hormone

C  Diminished endometrial tissue proliferation

D  Interference with the proliferation of the fertilized ovum

A  Follicle-stimulating hormone

B  Adrenocorticotropic hormone

C  Antidiuretic hormone

D  Luteinizing hormone

A  Weight gain

B  Thrombophlebitis

C  Hypertension

D  Dysmenorrhea

A  Nausea

B  Higher-pitched voice

C  Weight loss

D  Dry skin

A  Accelerated labor

B  Premature labor

C  Postpartum hemorrhage

D  Termination of pregnancy

A  Alendronate

B  Megestrol

C  Esterified estrogens

D  Medroxyprogesterone

A  Phase 2

B  Phase 1

C  Phase 3

D  Phase 4

A  Monophasic

B  Biphasic

C  Extended-cycle

D  Triphasic

A  Interstitial cell-stimulating hormone

B  Luteotropic hormone

C  Follicle-stimulating hormone (FSH)

D  Luteinizing hormone (LH)

A  Indomethacin

B  Methylergonovine

C  Medroxyprogesterone acetate

D  Megestrol

A  Magnesium sulfate

B  Oxytocin

C  Terbutaline

D  Methylergonovine

A  Clomiphene

B  Methylergonovine

C  Megestrol

D  Raloxifene

A  Day 14

B  Day 21

C  Day 3

D  Day 7

A  Adrenocorticotropic hormone

B  Antidiuretic hormone

C  Follicle-stimulating hormone (FSH)

D  Luteinizing hormone (LH)

A  The contractions can be fatal to the patient.

B  The fetal heart rate is stable.

C  The patient is ready for delivery.

D  The patient’s blood pressure is stable.

A  Presence of abnormal uterine bleeding

B  Current use of medications for depression

C  Current smoking status

D  Compliance with the fertility drugs

A  Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

B  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events

C  Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events

D  Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer